Boston Beer Company Inc
Beverages
Boston Beer Company Inc (SAM) Stock News
The latest SAM headlines and market coverage — 5 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
GOSSAMER BIO DEADLINE MONDAY JUNE 1st: Bragar Eagel & Squire, P.C. Urges Gossamer Bio, Inc. (NASDAQ:GOSS) Investors with Large Losses to Contact the Firm Before Monday June 1st
A class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) for allegedly providing materially false and misleading statements regarding its Phase 3 PROSERA study for pulmonary arterial hypertension treatment. The company is accused of expressing confidence in the trial design while concealing adverse facts about placebo response controls at Latin American testing sites, causing investors to purchase securities at artificially inflated prices. Investors who purchased shares between June 16, 2025, and February 20, 2026, have until June 1, 2026, to apply as lead plaintiff.
- GlobeNewswire Inc.·
GOSSAMER DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
Rosen Law Firm is notifying investors in Gossamer Bio, Inc., FS KKR Capital Corp., and Regencell Bioscience Holdings Limited of ongoing securities class action lawsuits. The firm is seeking lead plaintiffs with losses exceeding $100,000 before the June 1, 2026 deadline. The Gossamer case alleges defendants made false statements about their Phase 3 PROSERA study design while concealing material adverse facts.
- GlobeNewswire Inc.·
GOSSAMER DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – GOSS
Rosen Law Firm is encouraging investors who purchased securities in Gossamer Bio, Upstart Holdings, and FS KKR Capital Corp. during specified periods to join class action lawsuits. The firm is seeking a lead plaintiff for the Gossamer case by June 1, 2026, with allegations involving false statements regarding a Phase 3 clinical study.
- Benzinga·
STARLIGHT WESTERN CANADA MULTI-FAMILY (NO. 2) FUND ANNOUNCES Q1-2026 OPERATING RESULTS INCLUDING SAME PROPERTY NOI GROWTH OF 5.0%
TORONTO , May 20, 2026 /CNW/ - Starlight Western Canada Multi-Family (No. 2) Fund (the "Fund") announced today its results of operations and financial condition for the three months ended March 31, 2026 ("Q1-2026"). Certain comparative figures are included for the Fund's financial and operational performance as at December 31, 2025 and for the three months ended March 31, 2025 ("Q1-2025"). All amounts in this press release include amounts attributable to any non-controlling interests and are in thousands of Canadian dollars except for average monthly rent ("AMR") 1 , or unless otherwise stated. "We are pleased with the strength of performance during the quarter which achieved same property net operating income growth of 5.0%" commented Neil Fischler, Executive Vice President. "Management continues to focus on its active management strategy for the properties to maximize the unitholders value." Q1-2026 HIGHLIGHTS The Fund achieved AMR growth of approximately 3.9% between Q1-2025 and Q1-2026 including the impact of acquisition of Starlight Western Canada Multi-Family Limited Partnership ("SW1") properties during fourth quarter of 2025. The growth continues to be driven by sustained demand for multi-family suites and overall immigration levels in Canada and in particular, Vancouver Island and the mainland of the Province of British Columbia ("BC") (collectively, the "Primary Markets"). Revenue from property operations and net operating income ("NOI") 1 for Q1-2026 were $8,642 and $6,029 (Q1-2025 - $5,460 and $3,797), respectively, representing an increase in revenue and NOI of 58.3% and 58.8%, respectively, primarily due to the difference in the number of properties owned between the two periods ("Primary Variance Driver"). Same property net operating income ("Same Property NOI") 1 for Q1-2026 was $3,987 (Q1-2025 - $3,797), representing an increase of $190 or 5.0% relati
- GlobeNewswire Inc.·Bullish
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
Indivior presented new real-world data at the ASAM 2026 Annual Conference demonstrating that SUBLOCADE (monthly injectable buprenorphine) accounts for the smallest proportion of non-fatal and fatal overdose events compared to other medications for opioid use disorder. The company also presented findings from the ROUTE Study showing that remission from OUD correlates with improved quality of life,